Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | JAK1 | P23458 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16689787 | 0.89 | KMT2A (0.50) | MEN1KMT2AGRM5GPR119ESR2 | |
| SCHEMBL16681105 | 0.88 | MAPT (0.50) | MEN1KMT2AGPR119JAK2JAK1 | |
| SCHEMBL5383285 | 0.88 | KMT2A (0.43) | MEN1KMT2AGPR119JAK2JAK1 | |
| SCHEMBL27166187 | 0.88 | MEN1 (0.57) | MEN1KMT2AGRM5GPR119ESR2 | |
| SCHEMBL27166159 | 0.88 | JAK2 (0.40) | MEN1KMT2AS1PR2GPR119JAK2 | |
| SCHEMBL2405534 | 0.88 | KDM4E (0.48) | MEN1KMT2AGRM5GRM1GPR119 | |
| SCHEMBL27166100 | 0.87 | GPR119 (0.44) | MEN1KMT2AGRM5GPR119JAK2 | |
| SCHEMBL30055079 | 0.86 | GPR119 (0.53) | MEN1KMT2AGRM5GPR119 | |
| SCHEMBL27166173 | 0.84 | SMN1; SMN2 (0.46) | GPR119ESR2 | |
| SCHEMBL27166127 | 0.83 | JAK2 (0.43) | MEN1KMT2AGRM5GRM1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637471-B2 | Heterocyclic compounds, compositions, methods of preparation and uses thereof | ORGANON R&D FINLAND LTD. (FI) | 2026-05-26 | — | — | US | disclosed |
| EP-4334289-B1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | Organon R&D Finland Oy (FI) | 2025-06-25 | — | — | EP | disclosed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4469446-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| US-20240254131-A1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | ORGANON R&D FINLAND LTD. (FI) | 2024-08-01 | — | — | US | disclosed |
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4334289-A1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | Organon R&D Finland Ltd (FI) | 2024-03-13 | — | — | EP | disclosed |
| EP-4326714-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| CN-117295726-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2023-12-26 | — | — | CN | disclosed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | disclosed |
| WO-2022234193-A1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | FORENDO PHARMA LTD (FI) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022223750-A1 | HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2022-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP1A1, CYP4B1 | MEN1 176/4885KMT2A 2713/4885S1PR2 4174/4885 |
| US-20240254131-A1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | AKR1C3, AKR1C4, AKR1C1 | MEN1 3066/4885KMT2A 3679/4885S1PR2 1110/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | MEN1 2422/4885KMT2A 1346/4885S1PR2 4406/4885 |
| US-12637471-B2 | Heterocyclic compounds, compositions, methods of preparation and uses thereof | AKR1C3, AKR1C4, AKR1C2 | MEN1 3860/4885KMT2A 3376/4885S1PR2 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.